Key Metrics of Cpc Diagnostics Private Limited
About Cpc Diagnostics Private Limited
Sectors
Company details
Operational Areas of Cpc Diagnostics Private Limited
Company summary
Entity details
Compliance
Industry classification
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
Rating history
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 30 Mar 2026 | ICRA | Reaffirmed | BBB+ | A2 | Stable | ₹42.0 Cr | View |
Credit strengths (ICRA, Mar 2026)
+ Established presence in the medical instruments industry
The promoters have experience of more than three decades in the industry.
+ Healthy financial profile
The company witnessed a healthy revenue growth at a CAGR of around 25% over the last four years ending in FY2025, driven by healthy demand and increasing base of medical instrument installed base supporting growth in sales of reagents.
Credit challenges
− Medium revenue concentration in South India and moderate scale of operations
The company’s scale of operations is moderate, with revenues of Rs. 243.6 crore in 9M FY2026, despite healthy annualised growth of around 19% in the competitive medical instruments industry.
− Exposed to high supplier concentration risk
CPC is an exclusive supplier of reagents and medical instruments manufactured by EG and YHLO in India.
Could lead to an upgrade
ICRA could upgrade the ratings if the company diversifies its revenue profile through expansion to new geographies and addition of new products, leading to a substantial improvement in the scale of operations, while maintaining its capital structure and
Could lead to a downgrade
ICRA may downgrade the ratings if there is a sharp decline in the company’s profitability on a sustained basis or a sharp elongation in the working capital cycle, impacting the cash flows or debt protection metrics. Specific credit metrics for a rating downgrade would be Total debt/OPBIDTA of more than 2.3 times on a sustained basis.
Agency-reported financials (ICRA, 30 Mar 2026)
| Metric | FY2024 | FY2025 |
|---|---|---|
| Operating income | ₹246 Cr | ₹274 Cr |
| PAT | ₹9.50 Cr | ₹14.40 Cr |
| OPBDIT/OI | 16.2% | 14.7% |
| PAT/OI | 3.9% | 5.2% |
| Total outside liabilities/Tangible net worth (times) | 0.60× | 0.80× |
| Total debt/OPBDIT (times) | 0.50× | 1.00× |
| Interest coverage (times) | 12.80× | 10.30× |
| Revenue growth (YoY) | — | 11.8% |
| EBITDA (margin × income) | ₹39.77 Cr | ₹40.34 Cr |
| Implied total debt (debt/EBITDA × EBITDA) | ₹19.89 Cr | ₹40.34 Cr |
| Implied interest cost (EBITDA ÷ coverage) | ₹3.11 Cr | ₹3.92 Cr |
Borrowings & rated debt
Facility mix
Rated facilities
| Facility | Type | Previous | Current | Change | Rating | Action | Agency |
|---|---|---|---|---|---|---|---|
| Long-term – Fund-based – Cash Credit Long-term – Fund-based – Term | Working capital & bank lines | ₹35.5 Cr | ₹35.5 Cr | 0.0% | BBB+ (Stable) | Reaffirmed | ICRA |
| Loan Short-term – Non-fund based – Sub-limit Long-term Fund-based | Non-fund based limits | ₹5.85 Cr | ₹5.85 Cr | 0.0% | BBB+ (Stable) | Reaffirmed | ICRA |
| (1.50) (1.50) Overdraft | Working capital & bank lines | ₹48.0 L | ₹48.0 L | 0.0% | BBB+ / A2 (Stable) | Reaffirmed | ICRA |
| Long-term – Unallocated | Working capital & bank lines | ₹15.0 L | ₹15.0 L | 0.0% | BBB+ (Stable) | Reaffirmed | ICRA |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2024-25
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 62% |
| Information on file | 33% · missing: Audited financial statements (last 18 months), Annual results history (3+ years), Debt obligations and repayment schedule, Capex / investment plans, Auditor details, Shareholding pattern |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
- Credit outlook model: 62% chance the next rating action is stable or better
- Current rating BBB+ (investment grade)
- Interest coverage 10.3×
- ₹0.15 cr of rated limits not yet tied to a lender
Rated limits by facility
Timeline
From the report
However, the price escalation clause (with respect to forex prices) in the agreement with its customers mitigates the exchange rate fluctuation risk to an extent. www.icra.in Sensitivity Label : Public Page |2 Liquidity position: Adequate CPC’s liquidity position is adequate, supported by free cash balances of around Rs. 18.4 crore and unutilised working capital lines of around Rs. 20–25 crore, as on December 31, 2025, and expected cash flow from operations of Rs. 25–30.0 crore.
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Cpc Diagnostics Private Limited
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Medical Devices & Diagnostics · Pharmaceuticals & Healthcare | lupindiagnostics.com | — | Maharashtra, India | |
| Vijaya Diagnostic Centre Limited | · Community, personal and Social Services | — | — | Hyderabad, Telangana, India |
| Krsnaa Diagnostics Limited | · Business Services | — | — | Pune, Maharashtra, India |
| Suraksha Diagnostic Limited | Medical Devices & Diagnostics · Pharmaceuticals & Healthcare | — | — | Kolkata, West Bengal, India |
| Hemant Surgical Industries Limited | Medical Devices & Diagnostics · Pharmaceuticals & Healthcare | — | — | Maharashtra, India |
 Intuitive Surgical India Private Limited |
Part of Intuitive Surgical. | intuitivesurgical.com | — | Bangalore, Karnataka, India |
 Brainiac Healthcare Private Limited |
Medical Devices & Diagnostics · Community, personal and Social Services | brainiachealthcare.com | 2021 | Gujarat, India |
| Medical Devices & Diagnostics · Pharmaceuticals & Healthcare | span.co.in | 1976 | India | |
 Abbott (India) |
Part of Abbott Laboratories. | abbott.co.in | 1888 | Mumbai, India |
 VRR Diagnostic Services (India) |
Medical Devices & Diagnostics · Pharmaceuticals & Healthcare | vrrdiagnostics.in | 1987 | India |
Similar companies
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.